Management of acromegaly in Latin America: expert panel recommendations

Although there are international guidelines orienting physicians on how to manage patients with acromegaly, such guidelines should be adapted for use in distinct regions of the world. A panel of neuroendocrinologists convened in Mexico City in August of 2007 to discuss specific considerations in Latin America. Of major discussion was the laboratory evaluation of acromegaly, which requires the use of appropriate tests and the adoption of local institutional standards. As a general rule to ensure diagnosis, the patient’s GH level during an oral glucose tolerance test and IGF-1 level should be evaluated. Furthermore, to guide treatment decisions, both GH and IGF-1 assessments are required. The treatment of patients with acromegaly in Latin America is influenced by local issues of cost, availability and expertise of pituitary neurosurgeons, which should dictate therapeutic choices. Such treatment has undergone profound changes because of the introduction of effective medical interventions that may be used after surgical debulking or as first-line medical therapy in selected cases. Surgical resection remains the mainstay of therapy for small pituitary adenomas (microadenomas), potentially resectable macroadenomas and invasive adenomas causing visual defects. Radiotherapy may be indicated in selected cases when no disease control is achieved despite optimal surgical debulking and medical therapy, when there is no access to somatostatin analogues, or when local issues of cost preclude other therapies. Since not all the diagnostic tools and treatment options are available in all Latin American countries, physicians need to adapt their clinical management decisions to the available local resources and therapeutic options

Significant benefits of AIP testing and clinical screening in familial isolated and young-onset pituitary tumors

Context Germline mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene are responsible for a subset of familial isolated pituitary adenoma (FIPA) cases and sporadic pituitary neuroendocrine tumors (PitNETs). Objective To compare prospectively diagnosed AIP mutation-positive (AIPmut) PitNET patients with clinically presenting patients and to compare the clinical characteristics of AIPmut and AIPneg PitNET patients. Design 12-year prospective, observational study. Participants & Setting We studied probands and family members of FIPA kindreds and sporadic patients with disease onset ≤18 years or macroadenomas with onset ≤30 years (n = 1477). This was a collaborative study conducted at referral centers for pituitary diseases. Interventions & Outcome AIP testing and clinical screening for pituitary disease. Comparison of characteristics of prospectively diagnosed (n = 22) vs clinically presenting AIPmut PitNET patients (n = 145), and AIPmut (n = 167) vs AIPneg PitNET patients (n = 1310). Results Prospectively diagnosed AIPmut PitNET patients had smaller lesions with less suprasellar extension or cavernous sinus invasion and required fewer treatments with fewer operations and no radiotherapy compared with clinically presenting cases; there were fewer cases with active disease and hypopituitarism at last follow-up. When comparing AIPmut and AIPneg cases, AIPmut patients were more often males, younger, more often had GH excess, pituitary apoplexy, suprasellar extension, and more patients required multimodal therapy, including radiotherapy. AIPmut patients (n = 136) with GH excess were taller than AIPneg counterparts (n = 650). Conclusions Prospectively diagnosed AIPmut patients show better outcomes than clinically presenting cases, demonstrating the benefits of genetic and clinical screening. AIP-related pituitary disease has a wide spectrum ranging from aggressively growing lesions to stable or indolent disease course

Aplicación de Biodentine en Endodoncia Regenerativa

Universidad de Buenos Aires. Facultad de Odontología. Cátedra de Odontología Integral Niños. Buenos Aires, Argentina.Universidad de Buenos Aires. Facultad de Odontología. Cátedra de Odontología Integral Niños. Buenos Aires, Argentina.Universidad de Buenos Aires. Facultad de Odontología. Cátedra de Odontología Integral Niños. Buenos Aires, Argentina

Análisis de trastornos temporomandibulares en niños de 10 a 15 años

Fil: Cortese, S. Universidad de Buenos Aires. Facultad de Odontología. Cátedra Odontología Integral Niños; Argentina.Fil: Guitelman, I. Universidad de Buenos Aires. Facultad de Odontología. Cátedra Odontología Integral Niños; Argentina.Fil: Farah, C. Universidad de Buenos Aires. Facultad de Odontología. Cátedra Odontología Integral Niños; Argentina.Fil: Fridman, D. Universidad de Buenos Aires. Facultad de Odontología. Cátedra Odontología Integral Niños; Argentina.Fil: Mondello, A. Universidad de Buenos Aires. Facultad de Odontología. Cátedra Odontología Integral Niños; Argentina.Fil: Biondi, A. Universidad de Buenos Aires. Facultad de Odontología. Cátedra Odontología Integral Niños; Argentina.Objetivos: Estimar la frecuencia y tipo de trastornos temporomandibulares (TTM) en niños y relacionarlos con edad, sexo, apretamiento dentario, bruxismo diurno y nocturno

Lucha de clases, guerra civil y genocidio en la Argentina, 1973-1983: Antecedentes, desarrollo, complicidades

Índice Advertencia al lector El colectivo de investigación. Agradecimientos Inés Izaguirre Introducción: El problema y la historia de la investigación Inés Izaguirre PRIMERA PARTE Antecedentes teóricos e históricos Inés Izaguirre SEGUNDA PARTE Formación, desarrollo y derrota de una fuerza revolucionaria en Argentina TERCERA PARTE El embate contra la clase obrera CUARTA PARTE El mapa territorial del genocidio ANEXOs ANEXO DOCUMENTA

Cabergoline treatment in cats with diabetes mellitus and hypersomatotropism

The aim of this study was to evaluate the safety and efficacy of cabergoline to control hypersomatotropism (HST) and diabetes mellitus (DM) in cats. This was a prospective cohort study. Twenty-three cats with HST and concurrent DM were enrolled. Cats received a dose of 10 μg/kg cabergoline q48h PO for 6 months. Serum insulin-like growth factor 1 (IGF-1) and fructosamine concentrations, insulin dose and Insulin Resistance Index (IRI) were measured at the time of diagnosis of HST and at the start of cabergoline treatment (t0), and 3 months (t1) and 6 months (t2) during cabergoline treatment.Fil: Miceli, Diego Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; ArgentinaFil: García, Jorge D. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; ArgentinaFil: Pompili, Gustavo A. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; ArgentinaFil: Rey Amunategui, Juan P. Universidad Maimónides; ArgentinaFil: Ferraris, Sergio. Universidad Maimónides; ArgentinaFil: Pignataro, Omar Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Guitelman, Mirtha Adriana. Gobierno de la Ciudad Autonoma de Buenos Aires. Hospital General de Agudos Carlos Durand.; Argentin